A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

Trial Profile

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Brigatinib (Primary) ; Crizotinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTA 1L
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 04 Aug 2017 Planned End Date changed from 1 Apr 2021 to 30 Apr 2021.
    • 04 Aug 2017 Planned primary completion date changed from 1 Apr 2019 to 30 Apr 2019.
    • 04 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top